What does this research mean for the field?

Chemotherapy-induced skin reactions arise from a complex, dynamic interplay between direct tissue toxicity and immune-mediated mechanisms, resulting in overlapping clinical phenotypes rather than isolated pathogenic processes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To examine the interplay between direct tissue toxicity and immune-mediated mechanisms responsible for chemotherapy-induced skin reactions.

August 24, 2026Current Opinion in Allergy and Clinical Immunology

Between hypersensitivity and toxicity: the complex spectrum of chemotherapy-induced skin reactions

View Full Paper

Ask AI

Bookmark

Authors

MYMona-Rita Yacoub MCMaria Cilona ENEustachio Nettis

Discussion

Member takes

Overview

Narrative review reveals overlapping toxic and immune mechanisms in chemotherapy-induced skin reactions, suggesting multidisciplinary evaluation to prevent premature cancer treatment cessation.

Key Points

To examine the interplay between direct tissue toxicity and immune-mediated mechanisms responsible for chemotherapy-induced skin reactions.
Reviewed pathogenic pathways, clinical phenotypes, and management strategies for cutaneous adverse reactions caused by traditional chemotherapies, targeted agents, and immune checkpoint inhibitors.
Chemotherapy-induced skin reactions stem from dynamic interactions among direct keratinocyte injury, innate immune activation, cytokine-driven inflammation, and adaptive immune responses.
Clinical presentations reflect an overlapping spectrum encompassing toxic phenotypes (e.g., toxic erythema of chemotherapy, hand–foot syndrome) and immune-mediated hypersensitivities (e.g., urticaria, severe cutaneous adverse reactions, bullous pemphigoid).
Integrated allergologic workups and multidisciplinary collaboration enable precise phenotyping and safe drug rechallenge or desensitization, minimizing unnecessary anticancer treatment discontinuation.

Cite This Study

Yacoub et al. (2026) studied this question.

synapsesocial.com/papers/6a8c00c1bca056c88e6dfaca https://doi.org/10.1097/aci.0000000000001196

View Full Paper

Ask AI

Bookmark

August 24, 2026Current Opinion in Allergy and Clinical Immunology

Between hypersensitivity and toxicity: the complex spectrum of chemotherapy-induced skin reactions

View Full Paper

Ask AI

Bookmark

Authors

MYMona-Rita Yacoub MCMaria Cilona ENEustachio Nettis

Discussion

Member takes

Overview

Narrative review reveals overlapping toxic and immune mechanisms in chemotherapy-induced skin reactions, suggesting multidisciplinary evaluation to prevent premature cancer treatment cessation.

Key Points

To examine the interplay between direct tissue toxicity and immune-mediated mechanisms responsible for chemotherapy-induced skin reactions.
Reviewed pathogenic pathways, clinical phenotypes, and management strategies for cutaneous adverse reactions caused by traditional chemotherapies, targeted agents, and immune checkpoint inhibitors.
Chemotherapy-induced skin reactions stem from dynamic interactions among direct keratinocyte injury, innate immune activation, cytokine-driven inflammation, and adaptive immune responses.
Clinical presentations reflect an overlapping spectrum encompassing toxic phenotypes (e.g., toxic erythema of chemotherapy, hand–foot syndrome) and immune-mediated hypersensitivities (e.g., urticaria, severe cutaneous adverse reactions, bullous pemphigoid).
Integrated allergologic workups and multidisciplinary collaboration enable precise phenotyping and safe drug rechallenge or desensitization, minimizing unnecessary anticancer treatment discontinuation.

Cite This Study

Yacoub et al. (2026) studied this question.

synapsesocial.com/papers/6a8c00c1bca056c88e6dfaca https://doi.org/10.1097/aci.0000000000001196

View Full Paper

Ask AI

Bookmark